{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:07:30Z","timestamp":1787170050001,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      Urticaria is a disease where there is development of short-lived itchy wheals (hives), angioedema, or both.\n                      <jats:sup>[1]<\/jats:sup>\n                      With a lifetime prevalence of up to 22%, it is a widespread skin disorder that affects the general population. Urticarial episodes lasting longer than 6 weeks are considered chronic spontaneous urticaria (CSU).\n                      <jats:sup>[2,3]<\/jats:sup>\n                      Bilastine is a novel second-generation H1-antihistamine approved by the Drugs Controller General of India for the symptomatic treatment of CSU. Till date, there are very few studies in the Indian population comparing the efficacy and safety of bilastine with second-generation antihistaminic. Hence, the study was planned to assess and compare the efficacy and safety of desloratadine and bilastine in patients of CSU.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate and compare the efficacy of desloratadine and bilastine in patients of CSU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>It was a randomized, open-label, parallel group, comparative study conducted in 60 patients of CSU attending the dermatology outpatient department of a tertiary care teaching hospital. Patients were divided into 2 groups of 30 each. They received either desloratadine 5 mg or Bilastine 20 mg once daily for 6 weeks, and efficacy and safety were assessed at 2-, 4- and 6-week follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Difference in MTSS was significant in bilastine as well as desloratadine, which showed that bilastine was equally efficacious as desloratadine. Adverse events were reported more in the desloratadine group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bilastine is equally efficacious as desloratadine, and a favourable safety profile may make it a more tolerable H1-antihistaminic than desloratadine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/picr.picr_291_25","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:00:26Z","timestamp":1771675226000},"page":"162-166","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A prospective, observational study of efficacy and safety of desloratadine and bilastine in patients of chronic spontaneous urticaria"],"prefix":"10.4103","volume":"17","author":[{"given":"Suchi","family":"Bansod","sequence":"first","affiliation":[{"name":"Department of Pharmacology, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrunalini Vinay","family":"Kalikar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Sontakke","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh Ishwardas","family":"Mukhi","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Disease, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree Babanrao","family":"Supekar","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Disease, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha P.","family":"Pawar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Raj","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, GMCH, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"R1-20260710","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA (2) LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"key":"R2-20260710","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1067\/mai.2000.105706","article-title":"Chronic urticaria","volume":"105","author":"Greaves","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20260710","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMcp011186","article-title":"Clinical practice. Chronic urticaria and angioedema","volume":"346","author":"Kaplan","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-20260710","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5415\/apallergy.2016.6.1.56","article-title":"Role of bilastine in the management of allergic rhinitis and urticaria: An Asia-Pacific consensus statement","volume":"6","author":"M\u00f6sges","year":"2016","journal-title":"Asia Pac Allergy"},{"issue":"Suppl 86","key":"R5-20260710","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"R6-20260710","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaci.2010.06.047","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision","volume":"126","author":"Brozek","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20260710","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00126839-200506060-00005","article-title":"Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: Receptor selectivity and in vitro antihistaminic activity","volume":"6","author":"Corc\u00f3stegui","year":"2005","journal-title":"Drugs R D"},{"key":"R8-20260710","first-page":"1999","article-title":"Safety profile of bilastine: 2nd generation H1-antihistamines","volume":"16","author":"Scaglione","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R9-20260710","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0091270011407191","article-title":"Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: Results of a thorough QT study (TQTS) with QT-concentration analysis","volume":"52","author":"Tyl","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R10-20260710","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ijd.12250","article-title":"Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: A randomized, double-blind, 6-week trial","volume":"53","author":"Dakhale","year":"2014","journal-title":"Int J Dermatol"},{"key":"R11-20260710","first-page":"544","article-title":"Gender-related differences in chronic urticaria","volume":"151","author":"Cassano","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"R12-20260710","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"R13-20260710","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","article-title":"Comparison of the efficacy and safety of a multi-centre, double-blind, randomized, placebo-controlled study","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy"},{"key":"R14-20260710","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/picr.picr_28_23","article-title":"Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study","volume":"14","author":"Sinha","year":"2023","journal-title":"Perspect Clin Res"},{"key":"R15-20260710","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bcp.12421","article-title":"Bilastine vs. hydroxyzine: occupation of brain histamine H 1-receptors evaluated by positron emission tomography in healthy volunteers","volume":"78","author":"Farr\u00e9","year":"2014","journal-title":"British journal of clinical pharmacology"},{"key":"R16-20260710","doi-asserted-by":"crossref","first-page":"e00499","DOI":"10.1002\/prp2.499","article-title":"Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine","volume":"7","author":"Nakamura","year":"2019","journal-title":"Pharmacol Res Perspect."},{"key":"R17-20260710","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09546634.2019.1590522","article-title":"Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: An exploratory study","volume":"31","author":"Serra","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R18-20260710","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1468-3083.2006.01429.x","article-title":"Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria","volume":"20","author":"Lachapelle","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_291_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:57Z","timestamp":1787167077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_291_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_291_25","relation":{},"ISSN":["2229-3485","2229-5488"],"issn-type":[{"value":"2229-3485","type":"print"},{"value":"2229-5488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"2025-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}